Overview

Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

In this study, the safety, tolerability, and anti-tumor activity of BINTRAFUSP ALFA in combination with chemotherapy will be assessed in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Haider Mahdi

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Paclitaxel